Indegene reported exceptional Q3 FY26 results, achieving over 30% YoY revenue growth and surpassing $100 million in revenue for the first time. Revenue per employee exceeded $70K annually, marking the highest in the industry, driven by technology and AI. The company completed acquisitions of BioPharm and Warn & Co., expanding domain expertise and capabilities. Adjusted EBITDA rose to Rs. 1,747 million, growing 15.7% YoY.
Financial Performance Highlights
Indegene demonstrated strong financial performance in Q3 FY26:
- Revenue from Operations: INR 9,421 million, a 30.8% YoY increase.
- Adjusted EBITDA: INR 1,747 million, reflecting a 15.7% YoY growth.
- Profit After Tax (PAT): INR 1,026 million.
- Cash Reserves: INR 13,954 million.
Business Highlights
Key business metrics for the quarter include:
- Client Base: Increased to 86 active clients.
- Million-Dollar Clients: 52 clients now contribute over $1 million in revenue.
- Top 20 Revenue: 56% of revenue derived from the top 20 global biopharma companies.
- Delivery Metrics: Employee count stands at 5,497, with a voluntary attrition rate of 15.9%.
Segment Performance
The core segments (ECS & EMS) experienced a 17.0% QoQ growth in Q3 FY26, and 20.5% YoY growth YTD.
Strategic Initiatives and Expansion
Indegene completed the acquisitions of BioPharm and Warn & Co. to deepen domain expertise and high-value capabilities. The company is focused on:
- Deeper engagement with large pharma customers, with top accounts showing continued revenue growth.
- Broader targeting leading to a wider client base.
- Leveraging GenAI platforms across the commercial value chain.
Recognition
Indegene was recognized as one of the Best Companies for Women in India and awarded a Silver Medal by EcoVadis for ESG performance.
Source: BSE
